NCMAG110 Abiraterone acetate advice document: July 2023
Posted on:
Document Type
Process guidance
Summary
Treatment for newly diagnosed low-risk hormone sensitive metastatic prostate cancer patients who are not suitable for currently available on-label alternatives. (Off-label use)
Decision: supported